

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2019

Commission File Number: 001-37384

GALAPAGOS NV  
(Translation of registrant's name into English)

Generaal De Wittelaan L11 A3  
2800 Mechelen, Belgium  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [ X ] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

The information contained in this report on Form 6-K, including the exhibits, is hereby incorporated by reference into the Company's Registration Statements on Forms F-3 (File No. 333-230639) and S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263 and 333-231765).

---

On October 25, 2019, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) [Exhibit 99.1](#). Press release dated October 25, 2019

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**GALAPAGOS NV**  
(Registrant)

Date: October 28, 2019

/s/ Xavier Maes  
Xavier Maes  
Company Secretary

---

## Galapagos receives transparency notification from Wellington Management Group LLP

---

**Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from Wellington Management Group LLP.**

Pursuant to Belgian transparency legislation<sup>1</sup>, Galapagos received a transparency notification on 22 October 2019 from Wellington Management Group LLP, who indicated that, following a disposal of ordinary shares, the remaining 3,079,573 Galapagos ordinary shares held by its entirely-controlled subsidiary Wellington Management Company LLP represent 4.97% of the current 61,953,831 outstanding Galapagos shares and thus, with the ordinary shares portion of its total position, crossed below the 5% threshold of Galapagos' voting rights on 8 October 2019. In addition, through its wholly owned subsidiary Wellington Management Company LLP, it now also holds 615,676 American Depositary Shares and 8,322 equity swaps with expiration in 2020, bringing the new total number of voting rights for Wellington Management Group to 3,703,571, which represents 5.98% of total outstanding shares. The full transparency notice is available on the Galapagos website.

### About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The company's pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos' ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at [www.glpg.com](http://www.glpg.com).

### Contacts

#### Investors:

Elizabeth Goodwin  
VP IR  
+1 781 460 1784

#### Media:

Carmen Vroonen  
Senior Director Communications  
+32 473 824 874

Sofie Van Gijssel

Director IR  
+32 485 19 14 15  
[ir@glpg.com](mailto:ir@glpg.com)

Evelyn Fox

Director Communications  
+31 6 53 591 999  
[communications@glpg.com](mailto:communications@glpg.com)

<sup>1</sup> Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market